PD-L1 Expression in Mastocytosis
Open Access
- 13 May 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (9) , 2362
Abstract
Programmed death 1 (PD-1), when activated by its ligands PD-L1 and PD-L2, suppresses active immune cells in normal immune regulation to limit autoimmunity and, in tumors, as a mechanism of immune evasion. PD-L1 expression has been described as both a prognostic and predictive marker in many solid and hematologic neoplasms, as targeted therapies against the PD-1/PD-L1 interaction have gained clinical importance. PD-L1 expression has been assessed in a few studies on mastocytosis. We review this literature and the need for further investigation of the tumor-immune interaction in mastocytosis.Keywords
This publication has 15 references indexed in Scilit:
- Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology PerspectiveCurrent Oncology, 2018
- PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metricsDiagnostic Pathology, 2018
- Variability of PD-L1 expression in mastocytosisBlood Advances, 2018
- Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumorsMedicine, 2018
- Prognostic significance of PD-L1 in solid tumorMedicine, 2017
- Mastocytosis: 2016 updated WHO classification and novel emerging treatment conceptsBlood, 2017
- Expression of PD-L1 in mastocytosisJournal of the American Academy of Dermatology, 2016
- Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severityJournal of Allergy and Clinical Immunology, 2016
- Innate vs. Adaptive: PD-L1-mediated immune resistance by melanomaOncoImmunology, 2015
- PD-1 Regulates the Growth of Human Mastocytosis CellsAllergology International, 2013